Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 JUN 15 ... report that B1P development is IL-7R alpha-dependent, and negatively regulated by Bruton tyrosinekinase. Lymphoid characteristics of B1P were further studied with recombination ...
2009 MAR 4 ... mechanism for such requirements remains elusive. In this study, we identify Bruton's tyrosinekinase (Btk) as a linker connecting BCR signaling to actin dynamics and the Ag transport ...
2009 MAR 30 ... Fresh data on agammaglobulinemia are presented in the report 'Bruton's tyrosinekinase (Btk): function, regulation, and transformation with special emphasis on the PH ...
2009 NOV 9 ... protein in T-lymphocyte activation and function. The homolog of Itk in B cells is Bruton's tyrosine kinase, previously shown to bind and phosphorylate the transcription factor TFII-I." ...
2009 JUL 20 ... agammaglobulinemia is a prototypical humoral immunodeficiency with the mutation of the Bruton's tyrosine kinase gene. We investigated the gene mutation and clinical features of 30 Chinese X-linked ...
2009 JUL 13 ... to macrophages and effector CD4(+) Th2 cells and inhibited Th2 cytokine production in a Bruton's tyrosine kinase-dependent manner. Additionally, Retnla(-/-) AAMacs promoted exaggerated antigen-specific ...
2009 APR 27 ... and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosinekinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell ...
2009 MAR 2 ... pancreatic, gastric, colon and breast cancers; a first in class inhibitor of Bruton's tyrosinekinase (Btk) (PCI-32765) currently in a Phase I clinical trial and targeting B-cell ...
2009 MAY 4 ... primary immunodeficiency associated with mutations of the BTK (Bruton agammaglobulinemia tyrosinekinase) gene."
"Non-functional BTK leads to a severe decline in ...
2009 NOV 2 ... I molecules, on relatively primitive B cells, B-1 cells, suppresses TLR9 signaling via Bruton's tyrosine kinase (Btk) dephosphorylation, which leads to attenuated activation of nuclear factor. B ...
2009 JAN 21 ... production from select V region promoters and requires Bright dimerization, Bruton's tyrosinekinase (Btk), and the Btk substrate, TFII-I, for this activity. Defects in Bilk cause ...
2009 MAY 5 ... we found that B cells are needed for exosomal T-cell stimulation because Bruton tyrosinekinase deficient mice showed abrogated B-and T-cell responses after OVA-Exo ...
2009 MAR 30 ... Immunological Reviews. According to recent research from the United States, "The Tec (tyrosinekinase expressed in hepatocellular carcinoma) family of non-receptor tyrosine kinases ...
2009 OCT 5 ... (AB, EF and BG) and part of the beta D strand. These results are extended into Btk (Bruton's tyrosine kinase), a Tec family kinase linked to the B-cell deficiency X-linked agammaglobulinemia ...
2009 MAR 30 ... and function. Bright is a B-cell-restricted factor that complexes with Bruton's tyrosinekinase (Btk) and its substrate, transcription initiation factor-I (TFII-I), to activate ...
2009 JUN 15 ... indirectly regulated IL-18 release by indirectly inhibiting LPS-induced Bruton's tyrosinekinase expression in LPS-activated RA FLS. These findings suggest that miRNAs function ...
2008 NOV 3 ... partially sensitive to an IkappaB kinase (IKK) inhibitor, but not sensitive to a Bruton's tyrosine kinase (Btk) inhibitor. Moreover, both the DNA-binding activity and phosphorylation induced by ...
2008 DEC 22 ... Researchers detail in 'Bruton's tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells,' new data ...
